OptimizeRx Reports Third-Quarter Results for Period Ended September 30, 2026, With Details Unavailable
Key Facts
OptimizeRx reported results for the three months ended September 30, 2026, according to a news feed summary published on November 11. No third-quarter results figures or details of new financial guidance were available for verification. The company had scheduled a call to discuss the results for November 11, 2026, at 4:30 p.m. Eastern Time. In announcing the call, it said financial results would be issued in a press release before the call. The announcement follows a second quarter marked by lower revenue and a net loss under U.S. GAAP.
In the second quarter of 2026, OptimizeRx revenue was about $20.5 million, down 30% from $29.2 million in the same period of 2025, according to the company’s filing with the U.S. Securities and Exchange Commission. The company reported a U.S. GAAP net loss of $0.7 million, compared with net income of $1.5 million a year earlier. In the first quarter of 2026, revenue reached $19.8 million, down 10% year over year, while the net loss was $0.5 million. These consecutive quarterly results provide context for the importance of the third-quarter figures, but no verified data are available to determine whether the revenue or net income trend changed during the period.
In August, OptimizeRx maintained its fiscal 2026 guidance for revenue of between $95 million and $100 million and adjusted EBITDA of between $21 million and $25 million. That followed an update in May that lowered the annual revenue range to $95–100 million, while keeping the adjusted EBITDA range at $21–25 million. In November 2025, the company first issued 2026 guidance, setting revenue at between $118 million and $124 million and adjusted EBITDA at between $19 million and $22 million. These milestones reflect earlier revisions to the outlook, while no reliable confirmation of a new range after the third-quarter results announcement is available here. August’s figures therefore remain the latest annual guidance in the available sources.
In its third-quarter 2025 results, OptimizeRx said revenue rose 22% to $26.1 million, with U.S. GAAP net income of $0.8 million. Those figures provide the year-over-year comparison for the period ended in September 2026, but current-quarter data are unavailable to determine the change from that baseline. The company also announced a partnership with PulsePoint on October 27, 2026, giving the platform’s clients access to its electronic health record and e-prescription inventory, and adding 250,000 healthcare professional identifiers to the platform. The available information does not quantify the partnership’s impact on third-quarter results or annual guidance.
OptimizeRx shares, which trade under the ticker OPRX, closed at $9.35 on November 10, 2026, according to EL7 data. That price predates the results announcement and does not reflect the stock’s movement after its release. No verified reading for the following trading session is available to determine the market’s reaction to the figures or any guidance update. The company had announced that the results release would come before the November 11 call scheduled for 4:30 p.m. Eastern Time.